Alshukairi, Abeer N.Al-Omari, AwadAl-Tawfiq, Jaffar A.El-Kafrawy, Sherif A.El-Daly, Mai M.Hassan, Ahmed M.Faizo, Arwa A.Alandijany, Thamir A.Dada, AshrafSaeedi, Mohammed F.Alhamlan, Fatma S.Al Hroub, Mohammad K.Qushmaq, IsmaelAzhar, Esam I.2023-06-082023-06-082022Alshukairi AN, Al-Omari A, Al-Tawfiq JA, et al. Active viral shedding in a vaccinated hospitalized patient infected with the delta variant (B.1.617.2) of SARS-CoV-2 and challenges of de-isolation [published online ahead of print, 2022 Apr 28]. J Infect Public Health. 2022;15(6):628-630. doi:10.1016/j.jiph.2022.04.011https://hdl.handle.net/1805/33550This article is made available for unrestricted research re-use and secondary analysis in any form or be any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.In the era of SARS-CoV-2 variants and COVID-19 vaccination, the duration of infectious viral shedding and isolation in post vaccine breakthrough infections is challenging and depends on disease severity. The current study described a case of SARS-CoV-2 Delta variant pneumonia requiring hospitalization. The patient received two doses of BNT162b2 COVID-19 vaccines, and he had positive SARS-CoV-2 viral cultures 12 days post symptom onset. The time between the second dose of vaccine and the breakthrough infection was 6 months. While immunosuppression is a known risk factor for prolonged infectious viral shedding, age and time between vaccination and breakthrough infection are important risk factors that warrant further studies.en-USPublic Health EmergencyVaccineDelta variantViral sheddingCOVID-19Article